Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Avidity Biosciences, Inc. (RNA) Other Gross PP&E Adjustments (2019 - 2025)

Avidity Biosciences' Other Gross PP&E Adjustments history spans 7 years, with the latest figure at -$31.8 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments fell 579.85% year-over-year to -$31.8 million; the TTM value through Dec 2025 reached -$31.8 million, down 579.85%, while the annual FY2025 figure was -$31.8 million, 579.85% down from the prior year.
  • Other Gross PP&E Adjustments reached -$31.8 million in Q4 2025 per RNA's latest filing, down from -$20.9 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $25.9 million in Q2 2025 to a low of -$31.8 million in Q4 2025.
  • Average Other Gross PP&E Adjustments over 5 years is $1.0 million, with a median of $3.7 million recorded in 2021.
  • Peak YoY movement for Other Gross PP&E Adjustments: soared 884.63% in 2023, then crashed 579.85% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$7.9 million in 2021, then dropped by 1.02% to -$8.0 million in 2022, then rose by 10.94% to -$7.1 million in 2023, then skyrocketed by 193.12% to $6.6 million in 2024, then plummeted by 579.85% to -$31.8 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Other Gross PP&E Adjustments are -$31.8 million (Q4 2025), -$20.9 million (Q3 2025), and $25.9 million (Q2 2025).